版本:
中国

BRIEF-GSK's Mepolizumab meets endpoints in phase 3 EGPA study

Nov 23 Glaxosmithkline Plc :

* Mepolizumab meets endpoints in phase 3 egpa study

* Phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis

* Mepolizumab is not approved for use anywhere in world for EGPA.

* Will support GSK's plans to submit regulatory applications for this patient population, expected in 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐